aprevo® Digital Segmentation
Carlsmed, Inc. • Radiology • 11/03/2023
Device Purpose
The aprevo® Digital Segmentation software utilizes an AI-based algorithm to automatically segment spinal anatomy, primarily the lumbar region, from DICOM images, producing a 3D model for use by trained design personnel. Its purpose is to provide an efficient tool for creating these models, with non-clinical testing validating its segmentation accuracy through Intersection over Union scores and vertebral body labeling metrics.
Summary
The aprevo® Digital Segmentation is a software medical device designed for use by trained medical design personnel to perform digital image segmentation of the spine, with a primary focus on the lumbar anatomy. Its core methodology involves processing DICOM images as input. This process includes pre-processing steps to filter out soft tissue and accurately identify the spinal structure. The software then employs an artificial intelligence (AI)-based algorithm to automatically segment the identified spinal anatomy and subsequently render a 3D model of the spine as its output. The software's functionality enables users to import medical images and generate digital 3D models, specifically of the spine. While the software itself does not include integrated tools for users to directly review and edit the segmentation or the 3D models, its output files can be reviewed and utilized within broader workflows using third-party software. Non-clinical testing demonstrated the software's performance, with an Intersection over Union (IOU) score for segmentation exceeding an 80% acceptance criterion, and vertebral body labeling accuracy surpassing a 90% overall acceptance criterion. Sensitivity and specificity for this labeling also exceeded 80% each, validated using diverse datasets representing various populations and equipment to ensure clinical relevance.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the AI-based algorithm differentiate between various spinal pathologies (e.g., fractures, scoliosis, stenosis) during the segmentation process, and what is its accuracy for these specific conditions?; What are the specific characteristics of the "key cohorts" used in the validation datasets, and did performance vary significantly across these different demographic or pathological groups?; Given that the software outputs a 3D model without integrated editing tools, what are the typical third-party software solutions recommended or commonly used for subsequent review, modification, and application of these models in pre-surgical planning or device design?; What are the computational requirements (e.g., processing power, memory) for running the aprevo® Digital Segmentation software, and how does its processing time scale with the complexity or length of the spinal segment being analyzed?; How does the pre-processing step specifically filter soft tissue and identify the spine, and what is its robustness to variations in image quality or patient anatomy (e.g., obesity, severe degeneration)?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of SBOM, ML-BOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly